|
Abnormal behavior
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
The same effect was not observed for HDAC5+/- mice experiencing EST, suggesting that only ESI induces behavioral changes by acting precisely through HDAC5-related biological pathways.
|
28025089 |
2017 |
|
Abnormal behavior
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Together, our findings reveal a molecular mechanism by which cocaine regulates HDAC5 function to antagonize the rewarding impact of cocaine, likely by putting a brake on drug-stimulated gene expression that supports drug-induced behavioral changes.
|
22243750 |
2012 |
|
Acute kidney injury
|
0.200 |
Biomarker
|
disease |
RGD |
Cisplatin induces Sirt1 in association with histone deacetylation and increased Werner syndrome protein in the kidney.
|
21416250 |
2011 |
|
Acute lymphocytic leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
HDAC1 and HDAC4 showed high expression in T-ALL and HDAC5 was highly expressed in B-lineage ALL.
|
20636436 |
2010 |
|
Adjustment Disorders
|
0.300 |
Biomarker
|
group |
CTD_human |
Histone deacetylase 5 epigenetically controls behavioral adaptations to chronic emotional stimuli.
|
17988634 |
2007 |
|
Adult Glioblastoma
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
Methylation of the HDAC4, HDAC5 and HDAC6 genes was assessed in 29 tumor samples (astrocytomas grades I, III, and IV) and in the glioblastoma cell lines U87, U251, U343, SF188, and T98G by methylation-specific quantitative PCR (MSED-qPCR).
|
21508384 |
2011 |
|
Adult Medulloblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In addition, we conducted functional studies using siRNA-mediated knockdown of HDAC5 and HDAC9 in medulloblastoma cells.
|
20413433 |
2010 |
|
ALBINOIDISM, OCULOCUTANEOUS, AUTOSOMAL DOMINANT
|
0.010 |
Biomarker
|
disease |
BEFREE |
Interferon-inducible T-cell alpha chemoattractant (ITAC) induces the melanocytic migration and hypopigmentation through destabilizing p53 via histone deacetylase 5: a possible role of ITAC in pigment-related disorders.
|
27436825 |
2017 |
|
Alveolar rhabdomyosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
PAX3-FOXO1 also regulates histone deacetylase 5 (HDAC5) in ARMS cells, and results of RNA interference studies confirmed that PAX3-FOXO1-mediated repression of IL24 is HDAC5-dependent.
|
30190424 |
2018 |
|
Amyloidosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Dexmedetomidine attenuates the toxicity of β‑amyloid on neurons and astrocytes by increasing BDNF production under the regulation of HDAC2 and HDAC5.
|
30483749 |
2019 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.010 |
Biomarker
|
disease |
BEFREE |
In addition, network‑based meta‑analysis confirmed growth factor receptor‑bound protein 2 and histone deacetylase 5 as pivotal hub genes in PDAC compared with normal tissue.
|
31257501 |
2019 |
|
Aortic Aneurysm
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We also examined the expression of mRNA encoding enzymes that catalyze making and removing epigenetic modifications by real-time PCR: we found that mRNA levels of DNA methyltransferase (DNMT) 1 and DNMT3A were higher in the AAA than in the HC group, mRNA levels of methyl-CpG-binding domain protein (MBD) 2 and MBD4 were higher in the AAA than in the HC group (MBD2: 6.21 ± 2.57 vs 3.04 ± 1.45; MBD4: 7.76 ± 3.48 vs 4.97 ± 3.10; both P < 0.05), and mRNA levels of histone deacetylase (HDAC) 1 and HDAC5 were significantly up-regulated in the AAA compared with the HC group (HDAC1: 2.17 ± 1.18 vs 1.51 ± 0.99; HDAC5: 1.35 ± 0.49 vs 0.94 ± 0.76; both P < 0.05).
|
31001930 |
2019 |
|
Aortic Aneurysm, Abdominal
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We also examined the expression of mRNA encoding enzymes that catalyze making and removing epigenetic modifications by real-time PCR: we found that mRNA levels of DNA methyltransferase (DNMT) 1 and DNMT3A were higher in the AAA than in the HC group, mRNA levels of methyl-CpG-binding domain protein (MBD) 2 and MBD4 were higher in the AAA than in the HC group (MBD2: 6.21 ± 2.57 vs 3.04 ± 1.45; MBD4: 7.76 ± 3.48 vs 4.97 ± 3.10; both P < 0.05), and mRNA levels of histone deacetylase (HDAC) 1 and HDAC5 were significantly up-regulated in the AAA compared with the HC group (HDAC1: 2.17 ± 1.18 vs 1.51 ± 0.99; HDAC5: 1.35 ± 0.49 vs 0.94 ± 0.76; both P < 0.05).
|
31001930 |
2019 |
|
Arteriosclerosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Histone deacetylases (HDACs) regulate gene transcription by deacetylating lysine residues in histone and nonhistone proteins and a heightened HDAC activation, notably of HDAC5, is associated with vascular disorders, such as atherosclerosis.
|
30793765 |
2019 |
|
Arteriosclerosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Taken together, our results reveal that phosphorylation-dependent derepression of HDAC5 mediates flow-induced KLF2 and eNOS expression as well as flow anti-inflammation, and suggest that HDAC5 could be a potential therapeutic target for the prevention of atherosclerosis.
|
20042720 |
2010 |
|
Astrocytoma
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
Significantly increased methylation of the HDAC5 gene was observed in astrocytomas when compared to non-neoplastic brain samples (p=0.0007) and to glioblastomas cell lines (p=0.001).
|
21508384 |
2011 |
|
Atherosclerosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Taken together, our results reveal that phosphorylation-dependent derepression of HDAC5 mediates flow-induced KLF2 and eNOS expression as well as flow anti-inflammation, and suggest that HDAC5 could be a potential therapeutic target for the prevention of atherosclerosis.
|
20042720 |
2010 |
|
Atherosclerosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Histone deacetylases (HDACs) regulate gene transcription by deacetylating lysine residues in histone and nonhistone proteins and a heightened HDAC activation, notably of HDAC5, is associated with vascular disorders, such as atherosclerosis.
|
30793765 |
2019 |
|
Atrial Fibrillation
|
0.010 |
Biomarker
|
disease |
BEFREE |
Accordingly, HDAC3 inhibitors and HDAC5 nuclear boosters show protection from tachypacing-induced changes and therefore may represent interesting therapeutic options in clinical AF.
|
30321539 |
2018 |
|
Attention Deficit Disorder
|
0.200 |
Biomarker
|
disease |
RGD |
A comparison of molecular alterations in environmental and genetic rat models of ADHD: a pilot study.
|
18937310 |
2008 |
|
Bipolar Disorder
|
0.400 |
Biomarker
|
disease |
CTD_human |
Genome-wide association study identifies 30 loci associated with bipolar disorder.
|
31043756 |
2019 |
|
Bipolar Disorder
|
0.400 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study identifies 30 loci associated with bipolar disorder.
|
31043756 |
2019 |
|
Bone Density
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies.
|
19801982 |
2009 |
|
Bone Density
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies.
|
19801982 |
2009 |
|
Breast Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Inhibition of HDAC5-LSD1 axis with sulforaphane blocks breast cancer growth and combined treatment with LSD1 inhibitor improves the therapeutic efficacy of sulforaphane.
|
29633255 |
2018 |